Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fulcrum Therapeutics, Inc. - Common Stock
(NQ:
FULC
)
4.770
+0.220 (+4.84%)
Streaming Delayed Price
Updated: 2:42 PM EST, Dec 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fulcrum Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
July 24, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
July 16, 2024
Via
Benzinga
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
June 12, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
May 13, 2024
Via
Benzinga
Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 4/12
April 12, 2024
Via
Investor Brand Network
Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 3/6
March 06, 2024
Via
Investor Brand Network
Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
February 28, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
June 11, 2024
Via
Benzinga
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
June 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
FULC Stock Earnings: Fulcrum Therapeutics Beats EPS for Q1 2024
May 13, 2024
FULC stock results show that Fulcrum Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 13, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Earnings Preview: Fulcrum Therapeutics
February 26, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 13, 2024
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!
Via
InvestorPlace
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 13, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate in Upcoming May Conferences
May 09, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
May 08, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
May 06, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
April 15, 2024
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
March 29, 2024
Via
Benzinga
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
March 28, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 22, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
March 18, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
March 06, 2024
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 06, 2024
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.
Via
Benzinga
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
February 27, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
February 20, 2024
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.